Table 1.
Studies Investigating the Association Between VEGFA Genes and Retinopathy of Prematurity (ROP)
| Polymorphism | Study country | Subjects | Results | Reference |
|---|---|---|---|---|
| rs2010963 (−634G>C, +405G>C) |
United Kingdom | 91 treatment-requiring ROP (BW 779g [440–1185g], GA 25 wk [23–32 wk]), 97 non-treatment-requiring preterm infants (BW 920 g [448–2302g], GA 26 wk ± 2.9 wk) | Higher frequency G allele among infants with threshold ROP | 41 |
| Hungary | 115 treatment-requiring ROP (BW 1160g ± 270g, GA 28.5 wk ± 2.0 wk), 86 mild or no ROP (BW 1200g ±270g, GA 29.2 wk ± 2.9 wk) | Higher frequency C allele among treated infants | 137 | |
| Turkey | 42 treatment-requiring ROP (BW 1097.5g ± 264.3g, GA 28.2 wk ± 2.4 wk), 50 regressed ROP (BW 1253.0g ± 212.2g, GA 29.7 wk ± 2.0 wk), 31 no ROP (BW 1345.6g ± 225.9g) | No significant association | 138 | |
| United States | 61 stage 4/5 ROP (BW 882g [600–1300g], GA 26 wk [23–30 wk]), 61 normal controls (BW 2430–3960g, GA 34–40 wk) | No significant association | 139 | |
| Japan | 127 ROP (944g [3778–2168g], GA 27 wk [22–33 wk]), 77 no ROP (BW 1596g [692–2400g], GA 32 wk [22–33 wk]) | No significant association | 140 | |
| Egypt | 62 ROP (BW 1400g [1000–2110g], GA 32 wk [28–34 wk]), 40 no ROP (BW 1640g [1009–2800g], GA 33 wk [29–35 wk]) | High frequency of G allele in ROP | 42 | |
| Poland | 60 treatment-requiring ROP (BW 900g ± 225g, GA 26.7 wk ± 2.3 wk), 20 regressed ROP (BW 1029g ±231g, GA 27.5 wk ± 1.6 wk), 101 no ROP (BW 1153g ±225g, GA 29.2 wk ± 2.05 wk) | No significant association | 141 | |
| Iran | 15 treatment-requiring ROP (BW 879g ± 81g, GA 27 wk ± 13 wk), 30 regressed ROP (BW 884g ± 63g, GA 27 wk ± 12 wk), 66 no ROP (BW 980g ± 81 g, GA 27 wk ± 10 wk) | No significant association | 142 | |
| rs1547651 | Caucasian | 43 ROP, 299 no ROP (all subjects GA ≤ 28 weeks) | No significant association | 43 |
| rs3025039 (+936C>T) |
Caucasian | 43 ROP, 299 no ROP (all subjects GA ≤ 28 weeks) | No significant association | 43 |
| Iran | 15 treatment-requiring ROP (BW 879g ± 81g, GA 27 wk ± 13 wk), 30 regressed ROP (BW 884g ± 63g, GA 27 wk ± 12 wk), 66 no ROP (BW 980g ± 81 g, GA 27 wk ± 10 wk) | No significant association | 142 | |
| United States | 33 stage 4/5 ROP, 49 normal controls | No significant association | 143 | |
| Egypt | 62 ROP (BW 1400g [1000–2110g], GA 32 wk [28–34 wk]), 40 no ROP (BW 1640g [1009–2800g], GA 33 wk [29–35 wk]) | No significant association | 42 | |
| rs833058 | Italy | 43 ROP, 299 no ROP (all subjects GA ≤ 28 weeks) | No significant association | 43 |
| rs833061 (−460C>T) |
Italy | 43 ROP, 299 no ROP (all subjects GA ≤ 28 weeks) | No significant association | 43 |
| Hungary | 115 treatment-requiring ROP (BW 1160g ± 270g, GA 28.5 wk ± 2.0 wk), 86 mild or no ROP (BW 1200g ± 270g, GA 29.2 wk ± 2.9 wk) | High frequency of 460TT/405CC haplotype in treatment-requiring ROP | 137 | |
| Turkey | 42 treatment-requiring ROP (BW 1097.5g ± 270g, GA 28.2 wk ± 2.4 wk), 50 regressed ROP (BW 1253.0g ± 212.2g, GA 29.7 wk ± 2.0 wk), 31 no ROP (BW 1345.6g ± 225.9g) | No significant association | 138 | |
| United States | 61 stage 4/5 ROP (BW 882g [600–1300g], GA 26 wk [23–30 wk]), 61 normal controls (BW 2430–3960g, GA 34–40 wk) | No significant association | 139 | |
| +13553C>T | Japanese | 127 ROP (BW 944g [378–2168g], GA 27 wk [22–33 wk]), 77 no ROP (BW 1596g [692–2400g], GA 32 wk [22–33 wk]) | A significant association between the TT genotype and non-severe ROP for gestational age | 140 |
| +702C>T | United States | 33 stage 4/5 ROP, 49 normal controls | No significant association | 143 |
| +1612G>A | United States | 33 stage 4/5 ROP, 49 normal controls | No significant association | 143 |
| −2578C>A | United States | ROP (BW 2430–3960g, GA 34–40 wk), no ROP (BW 600–1300g, GA 23–30 wk) (number of patients not reported) | No significant association | 144 |
| Hungary | 90 treatment-requiring ROP (BW 1160g ± 300g, GA 28.5 wk ± 2.4 wk), 110 mild (stage 1 or 2) or no ROP (BW 1200g ± 280g, GA 28.5 wk ± 2.4 wk) | No significant association | 145 |
Table lists investigated polymorphism and presence of statistical significance. Where noted in the original study, information is provided in parentheses regarding the birth weight (BW) and gestational age (GA) of patients. Brackets denote range of patient values and ± denotes one standard deviation of range of each variable.